Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C35H56N6O5 |
| Molecular Weight | 640.8563 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@H](NC(=O)[C@H](C(C)C)N(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC3=CC=CC=C3
InChI
InChIKey=XSAKVDNHFRWJKS-IIZANFQQSA-N
InChI=1S/C35H56N6O5/c1-22(2)28(37-32(43)29(23(3)4)38(7)8)34(45)39(9)30(24(5)6)35(46)41-20-14-18-27(41)33(44)40-19-13-17-26(40)31(42)36-21-25-15-11-10-12-16-25/h10-12,15-16,22-24,26-30H,13-14,17-21H2,1-9H3,(H,36,42)(H,37,43)/t26-,27-,28-,29-,30-/m0/s1
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/9860873 | http://adisinsight.springer.com/drugs/800006853
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/9860873 | http://adisinsight.springer.com/drugs/800006853
Cemadotin (LU103793) is a cytotoxic water-soluble pentapeptide analogue of dolastatin 15. The dolastatin peptides were originally isolated from the shell-less mollusc Dolabella auricularia. Cemadotin blocks cells at mitosis. It exerts its antitumor activity by suppressing spindle microtubule dynamics through a distinct molecular mechanism by binding at a novel site in tubulin. Cemadotin was in phase II clinical trials as a promising cancer chemotherapeutic agent. However, this agent appears to be inactive in the treatment of advanced non-small-cell lung cancer and other tumors and this research has been discontinued.
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.75 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9704730 |
2.5 mg/m² single, intravenous dose: 2.5 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
CEMADOTIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.97 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9704730 |
2.5 mg/m² 1 times / day steady-state, intravenous dose: 2.5 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
CEMADOTIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.2 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9704730 |
3 mg/m² 1 times / day steady-state, intravenous dose: 3 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
CEMADOTIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10.1 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9704730 |
2.5 mg/m² single, intravenous dose: 2.5 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
CEMADOTIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
10.5 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9704730 |
2.5 mg/m² 1 times / day steady-state, intravenous dose: 2.5 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
CEMADOTIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
6.3 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9704730 |
3 mg/m² 1 times / day steady-state, intravenous dose: 3 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
CEMADOTIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
13 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9704730 |
2.5 mg/m² single, intravenous dose: 2.5 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
CEMADOTIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
10 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9704730 |
2.5 mg/m² 1 times / day steady-state, intravenous dose: 2.5 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
CEMADOTIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9704730 |
3 mg/m² 1 times / day steady-state, intravenous dose: 3 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
CEMADOTIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
17.5 mg/m2 1 times / day multiple, intravenous (total) Highest studied dose Dose: 17.5 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 17.5 mg/m2, 1 times / day Sources: Page: p.322 |
unhealthy, ADULT n = 3 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 3 Sources: Page: p.322 |
DLT: Neutropenia... Dose limiting toxicities: Neutropenia (grade 4, 100%) Sources: Page: p.322 |
12.5 mg/m2 1 times / day multiple, intravenous (total) MTD Dose: 12.5 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 12.5 mg/m2, 1 times / day Sources: Page: p.323 |
unhealthy, ADULT n = 6 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 6 Sources: Page: p.323 |
DLT: Neutropenia... Dose limiting toxicities: Neutropenia (grade 4, 16.7%) Sources: Page: p.323 |
2.5 mg/m2 1 times / day multiple, intravenous MTD Dose: 2.5 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.5 mg/m2, 1 times / day Sources: Page: p.2774 |
unhealthy, ADULT n = 12 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 12 Sources: Page: p.2774 |
DLT: Neutropenic fever... Dose limiting toxicities: Neutropenic fever (grade 3, 8.3%) Sources: Page: p.2774 |
3 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 3 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 3 mg/m2, 1 times / day Sources: Page: p.2773 |
unhealthy, ADULT n = 6 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 6 Sources: Page: p.2773 |
DLT: Neutropenia... Dose limiting toxicities: Neutropenia (66.7%) Sources: Page: p.2773 |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Neutropenia | grade 4, 100% DLT |
17.5 mg/m2 1 times / day multiple, intravenous (total) Highest studied dose Dose: 17.5 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 17.5 mg/m2, 1 times / day Sources: Page: p.322 |
unhealthy, ADULT n = 3 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 3 Sources: Page: p.322 |
| Neutropenia | grade 4, 16.7% DLT |
12.5 mg/m2 1 times / day multiple, intravenous (total) MTD Dose: 12.5 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 12.5 mg/m2, 1 times / day Sources: Page: p.323 |
unhealthy, ADULT n = 6 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 6 Sources: Page: p.323 |
| Neutropenic fever | grade 3, 8.3% DLT |
2.5 mg/m2 1 times / day multiple, intravenous MTD Dose: 2.5 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.5 mg/m2, 1 times / day Sources: Page: p.2774 |
unhealthy, ADULT n = 12 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 12 Sources: Page: p.2774 |
| Neutropenia | 66.7% DLT |
3 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 3 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 3 mg/m2, 1 times / day Sources: Page: p.2773 |
unhealthy, ADULT n = 6 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 6 Sources: Page: p.2773 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis. | 1995 Jul 15 |
|
| Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies. | 1998 Aug |
|
| Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeitsgruppe Pharmakologie in der Onkologie und Haematologie (APOH) Group of the German Cancer Society. | 1998 Dec |
|
| Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action. | 1998 Dec 15 |
Sample Use Guides
2.5 mg/m2 as a 5-minute infusion for 5 consecutive days every 3 weeks
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C67422
Created by
admin on Sat Dec 16 17:08:38 GMT 2023 , Edited by admin on Sat Dec 16 17:08:38 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000082045
Created by
admin on Sat Dec 16 17:08:38 GMT 2023 , Edited by admin on Sat Dec 16 17:08:38 GMT 2023
|
PRIMARY | |||
|
9812632
Created by
admin on Sat Dec 16 17:08:38 GMT 2023 , Edited by admin on Sat Dec 16 17:08:38 GMT 2023
|
PRIMARY | |||
|
C75875
Created by
admin on Sat Dec 16 17:08:38 GMT 2023 , Edited by admin on Sat Dec 16 17:08:38 GMT 2023
|
PRIMARY | |||
|
7399
Created by
admin on Sat Dec 16 17:08:38 GMT 2023 , Edited by admin on Sat Dec 16 17:08:38 GMT 2023
|
PRIMARY | |||
|
6SQ8M7ZSFV
Created by
admin on Sat Dec 16 17:08:38 GMT 2023 , Edited by admin on Sat Dec 16 17:08:38 GMT 2023
|
PRIMARY | |||
|
159776-69-9
Created by
admin on Sat Dec 16 17:08:38 GMT 2023 , Edited by admin on Sat Dec 16 17:08:38 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104387
Created by
admin on Sat Dec 16 17:08:38 GMT 2023 , Edited by admin on Sat Dec 16 17:08:38 GMT 2023
|
PRIMARY | |||
|
DTXSID70166723
Created by
admin on Sat Dec 16 17:08:38 GMT 2023 , Edited by admin on Sat Dec 16 17:08:38 GMT 2023
|
PRIMARY | |||
|
SUB07438MIG
Created by
admin on Sat Dec 16 17:08:38 GMT 2023 , Edited by admin on Sat Dec 16 17:08:38 GMT 2023
|
PRIMARY | |||
|
C094621
Created by
admin on Sat Dec 16 17:08:38 GMT 2023 , Edited by admin on Sat Dec 16 17:08:38 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
